tamoxifen

Anastrozole for DCIS may lead to increased rate of disease-free survival

Ductal carcinoma in situ (DCIS) is the presence of abnormal cells inside a milk duct in the breast. DCIS is considered the earliest form of breast cancer, and is the most common type of non-invasive breast cancer. DCIS

New, improved treatments reported at ASCO Cancer meeting

Cancer meeting reports improvements in survival for men with advanced prostate cancer and young women after breast cancer excision.

USPSTF recommendations on the use of breast cancer prevention drugs

In an update to its recommendations from 2002, the United States Preventive Services Task Force (USPSTF) continues to recommend the use of breast cancer

Tamoxifen helps lower risk of new breast cancer in BRCA mutation carriers, too

Since the 1970s, tamoxifen (developed by AstraZeneca) has been shown to prevent breast cancer recurrence secondary prevention in women who were surgically treated for a primary tumor. The drug is an estrogen-receptor modifier,